Emerging approaches for the treatment of hypertriglyceridemia.

Giuseppe Montalto, Manfredi Rizzo, Dragana Nikolic, Pablo Perez-Martinez, Jose Lopez-Miranda, Manfredi Rizzo

Risultato della ricerca: Article

7 Citazioni (Scopus)

Abstract

Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.
Lingua originaleEnglish
pagine (da-a)1869-1873
Numero di pagine5
RivistaExpert Opinion on Pharmacotherapy
Volume14
Stato di pubblicazionePublished - 2013

Fingerprint

Hypertriglyceridemia
Triglycerides
Cardiovascular Diseases
Dyslipidemias
LDL Lipoproteins
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Omega-3 Fatty Acids
Carrier Proteins
Fishes
Pharmacology
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cita questo

Emerging approaches for the treatment of hypertriglyceridemia. / Montalto, Giuseppe; Rizzo, Manfredi; Nikolic, Dragana; Perez-Martinez, Pablo; Lopez-Miranda, Jose; Rizzo, Manfredi.

In: Expert Opinion on Pharmacotherapy, Vol. 14, 2013, pag. 1869-1873.

Risultato della ricerca: Article

Montalto, G, Rizzo, M, Nikolic, D, Perez-Martinez, P, Lopez-Miranda, J & Rizzo, M 2013, 'Emerging approaches for the treatment of hypertriglyceridemia.', Expert Opinion on Pharmacotherapy, vol. 14, pagg. 1869-1873.
Montalto, Giuseppe ; Rizzo, Manfredi ; Nikolic, Dragana ; Perez-Martinez, Pablo ; Lopez-Miranda, Jose ; Rizzo, Manfredi. / Emerging approaches for the treatment of hypertriglyceridemia. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14. pagg. 1869-1873.
@article{490094f6bdb24f16a8293bac7658c63e,
title = "Emerging approaches for the treatment of hypertriglyceridemia.",
abstract = "Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.",
author = "Giuseppe Montalto and Manfredi Rizzo and Dragana Nikolic and Pablo Perez-Martinez and Jose Lopez-Miranda and Manfredi Rizzo",
year = "2013",
language = "English",
volume = "14",
pages = "1869--1873",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Emerging approaches for the treatment of hypertriglyceridemia.

AU - Montalto, Giuseppe

AU - Rizzo, Manfredi

AU - Nikolic, Dragana

AU - Perez-Martinez, Pablo

AU - Lopez-Miranda, Jose

AU - Rizzo, Manfredi

PY - 2013

Y1 - 2013

N2 - Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.

AB - Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.

UR - http://hdl.handle.net/10447/104538

UR - http://www.ncbi.nlm.nih.gov/pubmed/24011268

M3 - Article

VL - 14

SP - 1869

EP - 1873

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

ER -